A Phase 4 interventional study of Fingolimod and Standard MS DMT in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 13th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 4th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 19th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 15 in phase 4, and was the 7th registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
Drug: Fingolimod
Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
Drug: Standard MS DMT
0.5 mg/day oral capsule
Also known as: GILENYA™
Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
Also known as: Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia®
Change From Baseline in Patient-reported Treatment Satisfaction
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.
Time frame: baseline, 6 months
Change From Baseline in Patient-reported Activities of Daily Living (ADL)
The PRIMUS activity measure is a 15-item assessment used to evaluate patient-reported activities of daily living. The PRIMUS activities score was calculated summing the 15 items, after recoding the responses from 1 - 3 to 0 - 2. Therefore, the total score ranged from 0 - 3-, where high scores were indicative of greater function limitation. A negative change from baseline indicates improvement.
Time frame: baseline, 6 months
Change From Baseline in Patient-reported Fatigue
The fatigue Severity Scale (FSS) is a 9-item scale used to assess fatigue. The FSS score was calculated summing the 9 items of the questionnaire and dividing by the number of non-missing items (each item is based on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)). A negative change from baseline indicates improvement.
Time frame: 6 months
Change From Baseline in Patient-Reported Effectiveness and Convenience
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.
Time frame: 6 months
Change From Baseline in Patient-reported Depression
The Beck Depression Inventory Fast Screen (BDI-FS) is a brief, multiple choice, self reported inventory designed to evaluate depression in patients with medical illness. The BDI-FS score was calculated summing the 7 items of the questionnaire. Each item ranged from 0 (not present) to 3 (severe). The total score ranges from 0-3 (minimal depression), 4-8 (mild depression), 9-12 (moderate depression) and 13-21 (severe depression). A negative change from baseline indicates improvement.
Time frame: 6 months
Change From Baseline in Patient-reported Health Related Quality of Life (QOL)
The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, pain, general health, energy/fatigue, social functioning, role limitations due to emotional problems and emotional well-being. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.
Time frame: 6 months
Physician-reported Clinical Global Impression of Improvement (CGI-I)
The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. A lower score and a negative change from baseline indicate improvement.
Time frame: 6 months
Actual enrollment = 61 because 65 participants were randomized to the study, but only 61 participants received at least one dose of study medication. As such, the participant flow captures the 65 participants randomized and the 61 participants who received drug as the safety set.
| Milestone | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Started | 51 | 14 |
| Safety set | 50 | 11 |
| Completed | 47 | 5 |
| Not completed | 4 | 9 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Adverse event | 3 | 3 |
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.
| score on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Change From Baseline in Patient-reported Treatment Satisfaction | 19.57 ± 21.00 | 5.83 ± 16.47 |
The PRIMUS activity measure is a 15-item assessment used to evaluate patient-reported activities of daily living. The PRIMUS activities score was calculated summing the 15 items, after recoding the responses from 1 - 3 to 0 - 2. Therefore, the total score ranged from 0 - 3-, where high scores were indicative of greater function limitation. A negative change from baseline indicates improvement.
| score on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Change From Baseline in Patient-reported Activities of Daily Living (ADL) | 0.19 ± 2.75 | 0.15 ± 1.72 |
The fatigue Severity Scale (FSS) is a 9-item scale used to assess fatigue. The FSS score was calculated summing the 9 items of the questionnaire and dividing by the number of non-missing items (each item is based on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)). A negative change from baseline indicates improvement.
| score on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Change From Baseline in Patient-reported Fatigue | -0.18 ± 1.46 | -0.32 ± 1.21 |
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.
| score on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Effectiveness | 13.53 ± 28.39 | -1.67 ± 32.40 |
| Convenience | 24.64 ± 18.28 | 12.78 ± 25.26 |
The Beck Depression Inventory Fast Screen (BDI-FS) is a brief, multiple choice, self reported inventory designed to evaluate depression in patients with medical illness. The BDI-FS score was calculated summing the 7 items of the questionnaire. Each item ranged from 0 (not present) to 3 (severe). The total score ranges from 0-3 (minimal depression), 4-8 (mild depression), 9-12 (moderate depression) and 13-21 (severe depression). A negative change from baseline indicates improvement.
| score on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Change From Baseline in Patient-reported Depression | -1.15 ± 3.59 | -0.12 ± 3.06 |
The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, pain, general health, energy/fatigue, social functioning, role limitations due to emotional problems and emotional well-being. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.
| score on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Physical functioning (n=41,9) | 1.71 ± 23.07 | -1.11 ± 20.73 |
| Role limitations due to physical health (n=42,9) | 7.14 ± 37.97 | 5.56 ± 27.32 |
| Pain (n=45,9) | 6.56 ± 24.32 | 14.44 ± 15.25 |
| General health (n=44,8) | 4.52 ± 19.43 | 6.25 ± 14.08 |
| Energy/fatigue (n=43,9) | 2.33 ± 18.81 | 6.48 ± 33.24 |
| Social functioning (n=45,9) | 7.78 ± 24.90 | 6.94 ± 25.85 |
| Role limitations d/t emotional problems (n=45,9) | 7.04 ± 41.82 | 3.70 ± 38.89 |
| Emotional well-being (n=43,9) | 2.51 ± 16.88 | 4.89 ± 28.13 |
| PCS (n=40,8) | 4.52 ± 18.05 | 7.83 ± 15.86 |
| MCS (n=40,8) | 5.88 ± 18.21 | 7.28 ± 24.05 |
The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. A lower score and a negative change from baseline indicate improvement.
| Percentage of participants | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Much improved | 13.64 | 11.11 |
| Minimally improved | 36.36 | 11.11 |
| No change | 47.73 | 66.67 |
| Minimally worse | 2.27 | 11.11 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | — | 4/50 (8%) | 13/50 (26%) |
| Multiple Sclerosis Disease Modifying Treatment (MS DMT) | — | 1/11 (9.1%) | 7/11 (63.6%) |
| Event | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| Human papilloma virus test positiveInvestigations | 0/50 | 1/11 |
| LymphopeniaBlood and lymphatic system disorders | 2/50 | 0/11 |
| Drug ineffectiveGeneral disorders | 1/50 | 0/11 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 0/11 |
| Multiple sclerosis relapseNervous system disorders | 1/50 | 0/11 |
| Event | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) |
|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 8/50 | 0/11 |
| HyperthyroidismEndocrine disorders | 0/50 | 1/11 |
| Vision blurredEye disorders | 0/50 | 1/11 |
| Abdominal pain upperGastrointestinal disorders | 0/50 | 1/11 |
| NauseaGastrointestinal disorders | 0/50 | 1/11 |
| VomitingGastrointestinal disorders | 0/50 | 1/11 |
| Adverse drug reactionGeneral disorders | 0/50 | 1/11 |
| Influenza like illnessGeneral disorders | 1/50 | 1/11 |
| Injection site reactionGeneral disorders | 0/50 | 1/11 |
| HypertransaminasaemiaHepatobiliary disorders | 1/50 | 1/11 |
| Age, Continuous(Years) | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) | Total |
|---|---|---|---|
| Mean | 37.96 ± 8.69 | 35.82 ± 7.22 | 37.57 ± 8.43 |
| Sex: Female, Male(Participants) | Fingolimod | Multiple Sclerosis Disease Modifying Treatment (MS DMT) | Total |
|---|---|---|---|
| Female | 32 | 8 | 40 |
| Male | 18 | 3 | 21 |
The record gives a start of May 2011, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →